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Abstract
Parkinson’s disease is a common neurodegenerative condition that has
significant costs to the individual patient and to society. The pathology starts up
to a decade before symptoms are severe enough to allow a diagnosis using
current criteria. Although the search for disease-modifying treatment continues,
it is vital to understand what the right time is for diagnosis. Diagnosis of
Parkinson’s disease is based on the classic clinical criteria, but the presence of
other clinical features and disease biomarkers may allow earlier diagnosis, at
least in a research setting. In this review, we identify the benefits of an early
diagnosis, including before the classic clinical features occur. However, picking
the right point for a “timely” diagnosis will vary depending on the preferences of
the individual patient, efficacy (or existence) of disease-modifying treatment,
and the ability for health systems to provide support and management for
individuals at every stage of the disease. Good evidence for the quality-of-life
benefits of existing symptomatic treatment supports the argument for earlier
diagnosis at a time when symptoms are already present. This argument would
be significantly bolstered by the development of disease-modifying treatments.
Benefits of early diagnosis and treatment would affect not only the individual
(and their families) but also the wider society and the research community.
Ultimately, however, shared decision-making and the principles of autonomy,
beneficence, and non-maleficence will need to be applied on an individual
basis when considering a “timely” diagnosis.
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Parkinson’s disease (PD) is an age-related neurodegenera-
tive condition with a current prevalence of 41 out of 100,000 in 
people who are 40 to 49 years old, increasing to 1,607 out 
of 100,000 in those over the age of 80 years1–3. Global data 
indicate that PD will become a pandemic: prevalence more than 
doubled between 1990 and 2015, and PD now affects 6.2 
million individuals. Applying recent trends to global popula-
tion forecasts yields estimates of 12.9 to 14.2 million by 20401,2,4. 
Although it has often been said that people with PD do not 
have a shortened life span, there is evidence to the contrary5,6, 
and “healthy life” is substantially shortened for many patients. 
Premature death is even more apparent in PD patients with 
dementia7.
PD is widely recognized as the classic form of “the shaking 
palsy” or “paralysis agitans” first described by James Parkinson 
200 years ago8. The hallmark signs are bradykinesia (which 
describes decrement in a repetitive movement), rigidity, and 
tremor. Whereas these are the key motor features necessary 
for diagnosis, there are a host of non-motor symptoms which 
often emerge before the point of diagnosis. These non-motor 
symptoms convey a significant burden on the individual and 
their caregivers9. They include pain, autonomic features (such as 
constipation, hypotension, and erectile dysfunction), psychiatric 
disturbance (such as memory problems, affective disorders, 
and apathy), and other features, including fatigue, rapid eye 
movement (REM) sleep behavior disorder (RBD), smell loss, 
and hypersalivation9,10.
The motor symptoms are caused by destruction of dopaminer-
gic neurons, which occurs primarily in the substantia nigra11. 
As with other neurodegenerative diseases, an aberrant form of 
a naturally occurring protein—in this case, α-synuclein—is 
implicated in the pathological cascade. Protein aggregation 
and neuronal death occur long before overt clinical features 
manifest12–16. At the point of diagnosis, there has been a 50 to 
70% reduction in striatal dopamine and 30 to 50% of dopamin-
ergic neurons have been lost17,18. Intervention before neuronal 
loss is advanced, and slowing of the disease process are major 
priorities for PD research.
To intervene earlier, it must be possible to identify people 
before they would usually receive a diagnosis. However, it is 
important to be clear about the difference between an “early” and 
a “timely” diagnosis. From a scientific perspective, “early” is 
easy to comprehend within the framework of disease pathology 
and its manifestations. Most neurodegenerative processes follow 
a pattern of progression from the nascent or pre-diagnostic 
phase through categorical disease stages and ultimately death. 
This perspective is objective and necessary for the mapping 
out of relationships, processes, and treatments. Following on 
from progress made in infectious diseases and cancer, the axiom 
that earlier detection is better is hard to refute when there are 
drugs available that can change the underlying disease process. 
However, “timely” does not necessarily fit with this approach 
and may mean different things to different patients and indeed 
to society. We have moved further from the paternalistic 
doctor–patient relationship of previous generations and more 
toward a person-centered, individualized approach to health 
care. “Timely” puts an approach to diagnosis within the 
multiple spectra of the individual’s priorities and recognizes 
both the potential advantages and the disadvantages of an earlier 
diagnosis. These arguments, many of which hold true for PD, 
have been summarized in the context of dementia by Dhedhi 
et al.19 (Figure 1).
Current approach to diagnosis
The “gold standard” for the diagnosis of PD is postmortem path-
ological examination of the brain showing α-synuclein-posi-
tive inclusions in neuronal cells that have not died. The clinical 
diagnosis should be made by those with experience in PD and 
it is accurate about 85% of the time20. The most widely used 
diagnostic criteria for research are the United Kingdom 
Parkinson’s Disease Society Brain Bank Criteria, a three-step 
process that consists of confirming the presence of a Parkinso-
nian syndrome, ensuring the absence of any exclusion criteria, 
and establishing the presence of supportive criteria21. It is an 
iterative process, and although a diagnosis of PD can often be 
made at the first consultation, it is a diagnosis that requires 
periodic review to ensure that it remains the best explanation.
Given the fallibility of clinical diagnosis, revised methods 
of diagnosis and the search for biomarkers continue. The 
International Parkinson and Movement Disorders Society 
(MDS) has recently proposed an update to the clinical criteria 
for PD22. This allows a two-level diagnosis of “clinically estab-
lished PD” and “clinically probable PD”. It takes an algorithmic 
approach to establishing the presence of a parkinsonian 
syndrome and then checking for “supportive”, “red flag”, 
and “absolute exclusion” criteria. These new criteria have the 
benefit of bringing attention to many of the non-motor symp-
toms, but whether they result in higher diagnostic accuracy 
overall remains to be determined. Interestingly, despite huge 
efforts, biomarkers—clinical, genetic, biochemical, or imaging 
(for a summary, see 23)—still play essentially no role, and 
even functional neuro-imaging (that is, dopamine transporter 
single-photon emission computed tomography [SPECT]) is only 
mentioned in the new criteria as an absolute exclusion when 
normal. National guidelines in the UK also do not recommend 
any biomarkers for routine clinical use, explicitly recommend-
ing that magnetic resonance imaging not be used to confirm the 
diagnosis outside of the research setting24.
Approaches to “early” diagnosis
There has been growing attention to the pre-diagnostic phase of 
PD, and several studies have been initiated to better characterize 
this using a variety of risk factors and markers and prodromal 
features25–27. The Parkinson’s Associated Risk Study (PARS) 
is a multicenter US study comparing older adults with and 
without hyposmia and conducts annual physical assessments 
and two yearly dopamine transporter SPECT scans28. The PRIPS 
(Prospective Validation of Risk Factors for the Development of 
Parkinsonian Syndromes) study, in three European countries, 
compares risk factors, physical examination, smell, and tran-
scranial sonography in 1,847 adults older than 50 years29. The 
Tübingen Evaluation of Risk Factors for Early Detection of 
Neurodegeneration (TREND) cohort has followed nearly 700 
individuals (aged 50 to 85) enriched for possible pre-diagnostic 
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Figure 1. Arguments for and against “early” diagnosis. The ability to detect disease earlier is becoming more reliable, although no gold 
standard exists for a definitive diagnosis in life. However, as with all interventions in medicine, there are risks and benefits to an “early” 
diagnosis of Parkinson’s disease (PD). This figure summarizes the arguments. See Dhedhi et al. for a full discourse of these arguments 
relating to Alzheimer’s disease19.
symptoms. Participants were enrolled if they had at least one 
of the following symptoms: depression, reduced smell, or 
RBD. Biannual assessments included motor and neuropsy-
chological examinations, smell, quantitative gait and balance 
assessments, and transcranial sonography30. The Parkinson’s 
Progression Markers Initiative (PPMI) is a multinational 
cohort with recruitment in North America, Europe, Israel, and 
Australia. In addition to a longitudinal study of 423 individuals 
with established PD, there is a control cohort of 196 individuals 
(aged over 30 years) with neither PD nor a first-degree relative 
with PD and a further 65 individuals in a specific “at-risk” 
cohort with RBD or hyposmia. The investigators are continuing 
to recruit individuals with and without PD who carry mutations 
in moderate- to high-risk genes (LRRK2, GBA, or SNCA)31. In the 
UK, the PREDICT-PD study, which has been running since 
2011, has followed more than 1,300 older adults (aged from 60 
to 80 at entry) without a diagnosis of PD or other neurological dis-
ease. Annual online assessments track motor and non-motor symp-
toms through validated, evidence-based questionnaires, a tapping 
test for motor slowing32, and objective smell testing33,34. Although 
the methodologies vary, there is a clear indication that it is pos-
sible (and feasible) to detect people with strong evidence of 
“pre-diagnostic” PD through epidemiological, clinical, imaging, 
and other risk markers28,35–38. As many of these cohorts mature, 
the numbers of “high-risk” individuals “converting” to estab-
lished PD provide proof of concept and will help to establish 
the optimum approach to “early” detection. But whether this is 
“timely” remains a point of contention.
Separately, special mention should be given to the fact that a 
strong family history of PD or a genetically related condition 
could significantly alter an individual’s perspective on early versus 
timely diagnosis, but there also exists the opportunity for 
entry into genetically targeted disease-modifying treatment 
(DMT) trials. Gaucher’s disease (GD) is a lysosomal storage 
disease that is caused by mutations in the glucocerebrosidase 
gene (GBA). It has been recognized that individuals with type 1 
GD have a significantly increased risk of PD, and genetic testing 
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of unselected PD cohorts reveals GBA mutations in up to 10% 
(and is significantly higher in some populations, such as 
Ashkenazi Jewish PD cohorts)39–42. In some populations, particu-
larly Ashkenazi Jewish and Berber Arab populations, mutations 
in the leucine-rich repeat kinase 2 (LRRK2) gene are found in 
a significant proportion of individuals with PD, and the LRRK2 
prodrome and established PD phenotypes, as well as the 
pathology, may differ from “idiopathic” PD43–48.
In addition to publishing the revised clinical criteria for a 
diagnosis of PD, the MDS has published criteria for prodromal 
PD for use as a research tool26. These calculate a combined 
likelihood ratio for an individual using risk factors (age, sex, 
occupational toxin exposure, smoking and caffeine use, family 
history, and nigral hyperechogenicity using transcranial sonog-
raphy) and prodromal features (RBD, abnormal dopaminergic 
imaging, quantitative motor testing, hyposmia, constipation, 
hypotension, erectile and urinary dysfunction, and depression/ 
anxiety disorders). The cutoff for “probable prodromal PD” is at 
least 80% using the criteria and this has now been validated in 
several studies49–51.
When is the most “timely” diagnosis for an individual?
Timeliness of diagnosis is likely to depend on a number of 
personal and societal factors but also on the availability of 
effective treatments. Personal factors will vary according to the 
individual’s appetite for knowledge combined with their own 
weighting of various risk and symptomatic features. This is 
borne out in the variability of severity seen at first diagnosis 
of PD: some people seek medical attention at a stage where PD 
cannot be diagnosed by any current criteria, and some individuals 
put off seeking medical attention until overcome by a relatively 
severe burden of disease (for the full range, see Figure 2). In the 
absence of proven DMT, some may have a personal desire to know 
as early as possible (for instance, those with a family history or 
strong personal connection to PD). Others would welcome a 
diagnosis that explains mild symptoms, while many would 
continue to be diagnosed in the current way.
The timeliness of a diagnosis of established PD is still a matter 
of personal perspective, influenced by available treatment 
options. For many years, delaying anti-parkinsonian treatment 
was considered desirable in order to delay the onset of treatment 
complications and because of concerns about levodopa’s toxicity. 
However, the ELLDOPA (Early vs. Late Levodopa) trial 
showed that there was no clinical benefit in delaying levodopa 
and there is also no clinical evidence for levodopa toxicity52. 
On the other hand, for a newly diagnosed individual, there are 
both pharmacological and non-pharmacological interventions 
that increase quality of life. Treatments for the symptoms of PD 
are well established and effective. Observational studies show that 
people with PD who remain untreated (by mutual agreement 
Figure 2. The spectrum of timeliness. Parkinson’s has an insidious onset, and the pathology may start around a decade before diagnosis. 
Progressive pathology causes subtle motor and non-motor symptoms to gradually accumulate. When the timeliness of diagnosis is considered, 
a particular individual may fall into one of these four broad categories, depending on multiple factors and personal priorities. As disease-
modifying treatments become available, the arguments for moving the “timely” point earlier will become stronger. However, there cannot be a 
“one-size-fits-all” approach, and shared decision-making and personalized care will determine the optimal point for each person.
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between patient and physician) have worse quality of life across 
all domains of the PD-specific quality-of-life questionnaire 
(PDQ-39) when compared with those treated early with anti- 
parkinsonian medication53. It is plausible to extend this observa-
tion to those who are untreated by virtue of the fact that they are 
undiagnosed but may well be symptomatic. Non-pharmacological 
management of PD is also evolving. Exercise has been shown to 
be beneficial for both PD and Alzheimer’s disease (AD)54–56. Tai 
Chi and Qigong, dance, and other focused modes of physical 
activity have been reported to increase quality of life and have 
positive effects on other aspects of PD57,58. Furthermore, people 
with pre-diagnostic features of PD present to their primary care 
physicians more frequently, often many years before the diagno-
sis, suggesting that their symptoms are severe enough for them to 
seek treatment10. As many of these non-motor features are 
treatable, earlier diagnosis will help identify and treat these 
early features of PD. These observations all support the rationale 
of an early diagnosis at a time when symptoms first impact on 
a patient’s quality of life. This would bring forward the optimal 
time of diagnosis to the point where motor and non-motor 
symptoms first present to improve quality of life and long-term 
outcome of patients with PD.
However, when considering the possibilities, it should be noted 
that there has been a litany of failed drug trials aiming to alter 
the underlying disease process. These include nutraceuticals 
such as co-enzyme Q10, green-tea polyphenols, and creatine 
and pharmaceuticals, including rasagiline, pramipexole, and 
tocopherol59–61. Fortunately, the search is not over and is becoming 
not only more powerful but likely more successful. Several studies 
are targeting DMTs at particular genetic subgroups, including 
ambroxol for GBA carriers40,62 and LRRK2 competitive kinase 
inhibitors63, and antisense-oligonucleotide trials64 are beginning. 
The Linked Clinical Trials initiative has identified drugs with 
proven safety in other areas of medicine, which have sufficient 
existing data to warrant bringing them to clinical trials65. For 
example, there appears to be a relationship between diabetes 
mellitus and PD66, and exenatide is a hypoglycemic agent used 
for treating diabetes and has had promising results in a small 
randomized controlled trial in the UK67. A similar story may be 
emerging around the neuroprotective effects of statins, and a 
randomized controlled study of high-dose simvastatin is ongo-
ing in the UK68. Two studies that are testing vaccine approaches 
based on encouraging animal data are under way69. When any 
interventions are shown to delay onset or progression of PD, it 
is likely that bringing forward the diagnosis to a time when no 
treatable symptoms are apparent will become more attractive to 
individuals with increased risk.
Benefits beyond those to the individual?
The financial cost of PD is huge, not only for the individual 
and those close to them but also for society more generally70. In 
a large study of the economic impact of PD, Kowal et al. found 
that the cost of PD to the US exceeded USD $14 billion in 2010 
and that the PD population incurred more than twice as much 
medical expenditure as an equivalent population without PD71. 
In the UK, the overall cost of direct health expenditure is around 
twice that of age-, gender-, and geographically matched controls, 
and costs increase in line with disease progression72,73. In AD, 
economic modeling of DMTs indicates that net savings of as 
great as £3.3 billion per year are possible74. This suggests that, 
from a societal point of view, especially given the potential 
increased prevalence, “timely” diagnosis of PD would be as 
early as possible when disease-modifying interventions are 
available.
In addition, there is considerable importance of timely 
diagnosis to the research field. We have much to learn from 
recent clinical trials in AD. Unfortunately, all such trials so far 
have failed to meet their primary endpoints75. Although the rea-
sons for this are not clear and are probably multifactorial, some 
of the issues are also pertinent to PD research. A recurrent theme 
of articles reviewing the lack of efficacy of these AD DMTs is 
that they have all been “too little, too late”76,77. Similarly, for 
disease modification in PD to be most effective, it is desirable 
that initiation be before the majority of the nigrostriatum has 
been affected (that is, prior to the current point of diagnosis).
What, then, does a “timely” diagnosis entail?
In line with the approach of personalized care for an estab-
lished disease, the key to making a “timely” diagnosis is for the 
clinician to come to a mutual understanding with the patient 
and incorporate their understanding of the condition (and the 
likely progress ion of it), their goals, their fears, potential benefits, 
and possible harm (including medical and psychological)78. 
The clinician–patient decision-making process weighs up the 
perceived risks of early diagnosis against the potential benefits, 
thus maintaining the pillars of medical ethics: autonomy, benefi-
cence, non-maleficence, and justice. Although at present the 
benefits of early diagnosis for the individual are derived from 
symptomatic benefit, as more DMT trials are being offered to 
willing participants, more individuals are likely to define “timely” 
at an earlier stage.
In conclusion, there cannot be a one-size-fits-all approach to 
diagnosing PD. “Early” diagnosis exists in a purely temporal 
and mechanistic spectrum, whereas “timely” diagnosis is tailored 
to the individual, their priorities, their social milieu, and the 
therapeutic and health-system options in which they live. In 
addition to all the quantitative research that will be needed to 
find neuroprotective treatments, there is a need for robust quali-
tative research identifying societal attitudes to pre-diagnostic, 
prodromal, or pre-motor identification of pathology, and a 
personalized approach to diagnosis, based on the individu-
al’s attitudes, circumstances and available treatments, will be 
fundamental.
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